NCT00278642

Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders

High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Support in Patients With Autoimmune Bullous Skin Disorders: A Phase I Trial

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Richard Burt, MD · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Autoimmune Bullous Skin Disorders are believed to be due to immune cells, cells that normally protect the body and are now causing damage to the body. This study is designed to examine whether treating patients with high dose cyclophosphamide (a drug which reduces the function of the immune system) together with anti-thymocyte globulin (a protein that kills the immune cells that are thought to be causing your disease), followed by return of the previously collected special blood cells (stem cells) will result in improvement of this disease. Stem cells are undeveloped cells that have the capacity to grow into mature blood cells, which normally circulate in the blood stream. The purpose of the intense chemotherapy is to destroy the cells in the immune system which may be causing this skin disease. The purpose of the stem cell infusion is to restore the body's blood production, which will be severely impaired by the high dose chemotherapy and anti-thymocyte globulin.

Conditions

• Pemphigus

Interventions

Type	Name	Description
BIOLOGICAL	Hematopoietic stem cell transplantation	Autologous hematopoietic stem cell transplantation

Timeline

• Start date: 2002-09-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2006-01-18
• Last updated: 2013-04-08

Locations

1 site across 1 country: United States